Recursion Appoints Oncology Veteran Vicki Goodman As Chief Medical Officer To Drive Clinical Strategy

Recursion Pharmaceuticals has announced the appointment of Dr. Vicki Goodman as its new Chief Medical Officer, effective April 6, 2026. She will succeed Dr. David Mauro, who is stepping down after serving in the role for approximately three years. The leadership transition comes as Recursion advances its clinical pipeline and prepares for upcoming regulatory milestones.

“Recursion has been a remarkable place to serve, and I’m proud of what we’ve built together over the past several years,” said Dr. Mauro. “I’m especially grateful to my colleagues across clinical development and the broader organization for their collaboration and commitment to patients. I believe Recursion is uniquely positioned at the intersection of technology and drug development, and I look forward to watching the continued progression of the pipeline to potential treatments for patients in the years ahead.”

Dr. Goodman brings over two decades of experience in oncology drug development and medical leadership across biotech, large pharmaceutical companies, and regulatory agencies. Most recently, she served as Chief Medical Officer at Mural Oncology, where she led development efforts for a portfolio of cytokine-based therapies. Prior to that, she held senior leadership roles at Exelixis, overseeing clinical development, regulatory strategy, and medical affairs across multiple programs.

“On behalf of everyone at Recursion, I want to thank Dr. Mauro for his leadership, partnership, and many contributions to our clinical organization and pipeline,” said Najat Khan, Ph.D., CEO and President of Recursion. “Since joining Recursion, David has helped strengthen our medical organization, guided the advancement of our clinical portfolio, and supported important milestones across our programs, including the continued progression of REC-4881. We are grateful for his dedication to our mission.”

Her extensive career also includes key oncology leadership roles at Merck & Co., where she contributed to the development of major therapies such as KEYTRUDA®, and at Bristol Myers Squibb, where she supported the advancement of immuno-oncology drugs including OPDIVO® and YERVOY®. Earlier, at GlaxoSmithKline, she played a role in developing dabrafenib through regulatory approval, and she also began her career as a medical officer at the U.S. Food and Drug Administration.

“We are very excited to welcome Dr. Goodman to Recursion. Vicki's depth of clinical development experience, sound judgment, and the clarity with which she approaches advancing programs through critical regulatory and clinical inflection points are the leadership skills that will help us advance our clinical pipeline,” said Najat Khan, Ph.D., CEO and President of Recursion. “This combination of experience, especially at the later stages of clinical development, will be invaluable as we translate scientific insight into disciplined, high-quality programs and deliver differentiated medicines for patients.”

Recursion highlighted that Dr. Goodman’s experience in translating scientific innovation into successful clinical programs will be critical as the company progresses its pipeline. Her appointment is expected to strengthen the company’s clinical strategy and execution as it moves toward key development and commercialization milestones.

“Recursion stands apart in the industry through its ambitious integration of scientific and technological rigor to reimagine how medicines are discovered and developed through the power of AI,” said Dr. Goodman. “I’m thrilled to join the company at such an important moment. I look forward to working with Najat, the leadership team, and the broader organization to advance the pipeline, support smart and disciplined development decisions, and help bring impactful new therapies to patients.”